Biomarkers to Discern Transplantation Tolerance after Allogeneic Hematopoietic Cell Transplantation  by Pidala, Joseph et al.
REVIEWFrom the
2Micr
Moffi
Scien
Financial d
Correspon
Cance
FL 33
Received S
 2010 Am
1083-8791
doi:10.101Biomarkers to Discern Transplantation Tolerance
after Allogeneic Hematopoietic Cell Transplantation
Joseph Pidala,1,5 Gregory C. Bloom,3,5 Steven Enkemann,2,5 Steven Eschrich,3,5
Johnathan Lancaster,4,5 Claudio Anasetti1,5Although it is commonly accepted that allogeneic hematopoietic cell transplant (HCT) recipients develop
transplantation tolerance and can quickly discontinue all immunosuppressive drugs, existing data does not
support this concept. Most patients will require a prolonged duration of immunosuppression, lasting com-
monly several years. This has even greater importance, as the majority of transplants are now performed
utilizing peripheral blood mobilized stem cells, which are associated with an increased risk of chronic
graft-versus-host disease (cGVHD) and prolonged duration of immunosuppression. Despite these chal-
lenges, the approach to liberation from immunosuppression after HCT is empiric, and biomarkers of oper-
ational tolerance after HCT are lacking. Conversely, investigators in solid organ allografting have begun to
examine tolerance associated gene expression in renal and hepatic allograft recipients. Significant challenges
in the design and interpretation of these studies potentially limit comparisons. However, a relatively unified
model is beginning to emerge, which largely recapitulates previously established mechanisms of immune
tolerance. This evidence supports a state of immune quiescence with reduced expression of costimulation
and immune response genes, and upregulation of cell cycle control genes. Data indirectly supports the
importance of tumor growth factor (TGF)-b, supports the role of CD41CD251 regulatory T cells, and
offers new insights into the role of natural killer (NK) cells. Distinct in hepatic allograft tolerance, emerging
evidence highlights the importance of gdT cells, and selection of the Vgd11 subtype among the gdT cell
population. The deficiencies in the current understanding of transplantation tolerance after HCT, as well
as the inadequacies evident in the current empiric approach to immunosuppressive medication (IS) manage-
ment after HCT make clear the rationale for investigation aimed at elucidating tolerance associated bio-
markers after HCT.
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expressionINTRODUCTION
In the field of transplantation, a major unsolved
problem is immunologic tolerance. Immunosuppres-
sive medications (IS) allow the transplantation of allo-
grafts without life-threatening overactivated immune
response, but several issues remain. In solid organ
transplantation, most recipients will require life-long1Departments of Blood and Marrow Transplantation;
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6/j.bbmt.2009.11.009IS and suffer the morbidity of this therapy, yet, they
still are at risk for acute and chronic graft rejection.
In allogeneic hematopoietic cell transplantation
(HCT), immunosuppression is necessary to prevent
graft rejection and also to temper an immunologic re-
action of donor immune cells against the host. This re-
action, namely, graft-versus-host disease (GVHD), is
the major source of treatment-related morbidity and
mortality (TRM). Importantly, efforts at liberation
from IS are empiric, as clinicians are unable to discern
drug-suppressed immune response from the develop-
ment of tolerance. A state of operational tolerance, de-
fined as stable graft function and absence of ongoing
immunologic injury because of incompatibility be-
tween donor and recipient in the absence of ongoing
IS therapy, is infrequently reached in solid organ allog-
rafting. Novel investigation utilizing gene expression
profiling after solid organ transplantation has begun
to identify biomarkers of tolerance that may ultimately
allow for rational trials of immunosuppression729
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conduct and interpretation of this work, a preliminary
profile of immunoregulatory cells and differential gene
expression is beginning to emerge. Much of the find-
ings recapitulate previous experimentally established
mechanisms integral to immunologic tolerance. We
begin here by reviewing mechanisms of immunologic
tolerance, and then provide a conceptual framework
for microarray analysis of gene expression. Next, we
review the literature on tolerance-associated gene
expression and immunophenotyping to date in renal
and hepatic transplant. Challenges in the design and
analysis of this work are then discussed. A provisional
unifying model of tolerance-associated gene expres-
sion is presented. Finally, we conclude with a discus-
sion of future directions of this work with attention
to its application to allogeneic HCT.IMMUNOLOGIC TOLERANCE
Immunologic tolerance is a complex process that,
in the case of transplantation of allogeneic hematopoi-
etic stem cells (HSCs) or solid organs, is clinically
characterized by stable graft function and absence of
ongoing immunologic injury because of incompatibil-
ity between donor and recipient—as manifested by
GVHD in allogeneic HCT or graft rejection in solid
organ transplantation—in the absence of ongoing IS
therapy [1-3]. Investigation into the molecular mecha-
nisms responsible for immunologic tolerance has
implicated several active processes [4-7]. Through
central deletion, developing T cells with high affinity
T cell receptors (TCRs) for major histocompatibility
complex (MHC)/antigen complex presented by thy-
mic antigen presenting cells (APCs) undergo apoptosis
[8]. As HCT facilitates central tolerance, the major
problem after HCT is failure to achieve peripheral
tolerance. Mature T cells may undergo peripheral
deletion after presentation of self-antigen by dendritic
cells (DCs) under noninflammatory conditions, with
exhaustion after antigenic stimulus, or through the
suppression by regulatory cells [9-12]. T cells may
also become anergic through mechanisms including
incomplete costimulatory molecule signaling [13-18],
exposure to low-affinity antigenic ligands, through
cytokines elaborated by tolerogenic DC [19,20], and
through suppressive effects of regulatory T cells [21-
26]. Tolerance has also been experimentally estab-
lished by the induction of mixed host-donor chime-
rism [27-32]. As well, both naturally occurring and
inducible CD41CD251FoxP31 regulatory T cells
have been shown to be important mediators of
immune tolerance; their suppressive effect is thought
to be mediated through cell contact, as well as medi-
ated by tumor growth factor (TGF)-b, leading to
suppression of alloreactive T cells. TGF-b has also
been shown to have important effects on DC, leadingto their tolerogenic effect on T cells [25,33-39]. B
cell deletion and anergy [40,41] are not thought to be
relevant mechanisms of immune tolerance after
HCT. Finally, emerging work has shed new light on
the importance of the innate immune system, includ-
ing natural killer (NK) cells, which have been shown
to be important mediators of transplantation tolerance
through effects on antigen presenting cells and allor-
eactive T cells [42-45]. In total, experimental evidence
to date demonstrates a diversity of mechanisms under-
lying immune tolerance.MICROARRAYANALYSIS
Microarray technology provides an opportunity to
simultaneously analyze the expression of thousands of
genes. Investigations using this technology have pro-
vided an improved understanding of the molecular
mechanisms of disease, characterization of disease
classes, prognostic classification, and the development
of biomarkers for response to treatment. The power of
microarray technology is not just in the thousands of
genes that are measured in a single assay, but also in
the ability to archive the data and use it again to
address different biological questions.
Structurally, the microarray platform consists of
DNA, either synthesized oligonucleotides or purified
cDNA molecules, affixed to a structural support.
These probes are used to capture labeled target mole-
cules from an experimental sample. By quantifying the
amount captured, a measure is made of each individual
RNA species in a complex mixture from cells or tissues
[1,46-50]. The data is further evaluated for quality to
remove questionable data, normalized to account for
array-to-array intensity bias, and filtered to remove
background signal noise.
As in standard biological experimentation, the key
factors in successful microarray analysis are solid
experimental design and the correct selection of bio-
logical samples, ensuring that the output of the analy-
sis is related to the biological question at hand. Several
methods are available for the actual analysis of micro-
array data [48,51,52]. The initial step is usually a statis-
tical filtering for genes that are differentially expressed
between samples of 2 different classes, such as control
versus experimental. The analysis might use a standard
Student’s t-test or statistical analysis of microarrays
(SAM) [53]. This technique uses a modified t-test
coupled with a permutation analysis to control for false
discoveries. However, many other statistical methods
have been used. In direct class comparisons, the end
result is normally a list of the potential gene expres-
sion differences between the 2 classes. Additionally,
methods exist for comparing multiple classes to each
other. This analysis often involves a clustering or clas-
sification algorithm such as prediction analysis of mi-
croarrays (PAM) [54]. The goal of clustering is to
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perimental sample and to delineate how closely each of
the groups is related.
Microarray experiments generally involve far more
genes than samples, and care must therefore be taken
to address and/or correct for false discovery caused
by multiple testing. Interpreting the results in the
context of the biologic system in question can assist
in selection of relevant genes during this step.
In some cases, a classifier is constructed to separate
new samples into biologically relevant classes. The
accepted practice in classifier construction is to use
a training set of data for which the phenotype of inter-
est is known for each sample. The gene expression
values are used to teach the classifier to categorize
the samples according to their class phenotype. Proof
of the correctness of the developed classification
scheme is then realized with a test set of data. Good
classification accuracy on an independent group of
samples is the best assurance of the quality of the
classifier. Although many components of microarray
analysis are still the focus of active investigation, this
powerful tool makes possible an enhanced understand-
ing of the molecular underpinnings of biological
processes. This technology has been utilized to better
understand the nature of transplantation related
immune tolerance.MICROARRAYANALYSIS OF SOLID-ORGAN
TRANSPLANTATION IN THE CLINICAL
SETTING
Several studies have utilized microarray technol-
ogy to investigate transplantation tolerance. The ulti-
mate goal of such work is to define a gene expression
and cellular composition profile in allograft recipients
that would indicate whether or not it is possible to
liberate these patients from IS safely. These studies
have compared gene expression between operationally
tolerant individuals, variably defined nontolerant com-
parators (chronic rejection versus those that have
attempted and failed IS taper), and healthy control
subjects. The design of these studies, which have
been driven by pragmatic concerns given the rarity of
tolerant solid organ allograft recipients, makes it diffi-
cult to discern whether the differential gene expression
reported is because of immunosuppressive drugs (ie,
on IS versus off IS), immunologic resting versus active
state (ie, normal versus rejection), or a tolerant versus
nontolerant state; although the denominator, or total
number of subjects from which these subjects were
selected, is not provided in these studies, the tolerant
clinical phenotype is reported to be \5% in renal
allografts and \20% in hepatic allografts. Although
these are significant challenges to the interpretation
of this work, similarities in the results emerge thatreinforce concepts developed by prior laboratory
experimentation.
Brouard et al. [55] studied differential gene expres-
sion in peripheral bloodmononuclear cells (PBMC) on
a lymphochip platform comprised of 11,820 genes with
the aim of discerning biomarkers for operational toler-
ance in renal transplant recipients. The study sample
was divided into a training and test set. The training
group consisted of 5 tolerant (TOL) subjects (defined
as IS free for at least 2 years with stable graft function),
11 chronic rejection (CR) subjects (defined by clinical
and biopsy-proven chronic rejection), and 8 healthy
control (N) subjects. The investigators identified a 49
gene signature by PAM, and then applied this classifier
to the test set, where the sensitivity and specificity were
90% and 100%, respectively. Validation was also per-
formedwith reverse transcriptase-polymerase chain re-
action (RT-PCR). The investigators also examined the
prevalence of this 49 gene signature in MIS (defined as
those on steroid monotherapy) and STA (stable on
long-term IS) subjects; 50% of the MIS subjects and
1 of 12 STA subjects fit this phenotype. Although this
finding may provide rationale for IS liberation in this
large proportion of cases on steroid monotherapy,
this couldonlybeconclusivelydetermined inaprospec-
tive trial of IS liberation.
Several important insights emerge from this work:
first, the investigators confirm previous experimental
literature, demonstrating significantly increased ex-
pression of FOXP3, as well as increased expression
of neuropilin-1 and GITR in the TOL group [56-
58]. Second, they identified 3 distinct gene clusters
that separated the TOL from CR subjects, including
reduced immune activation, downregulation of signal
transduction genes and RNA binding genes, as well
as upregulated cell cycle regulator genes [55,59,60].
Next, prior evidence of the importance of TGF-b in
immune tolerance is corroborated; although the abso-
lute serum levels of TGF-b did not differ across
groups, 27% of the differentially expressed genes in
TOL versus CR are regulated by TGF-b [61-63].
Also, in support of major established mechanisms of
immune tolerance, the authors demonstrated reduced
expression of genes relevant to T cell costimulation,
T cell activation, cytotoxicity effectors, and pro-
inflammatory cytokines. In total, these findings sup-
port a state of immune quiescence, and recapitulate
several previously established mechanisms of immune
tolerance [55,64,65].
Braud et al. [66] studied differential gene expres-
sion in PBMC of renal allograft recipients using
cDNA arrays. This platform consisted of 6864 genes
chosen based on their relevance to immunology, apo-
ptosis, and cell signaling. A training set consisted of 8
TOL renal allograft recipients (defined here as sus-
tained stable graft function .1 year out from success-
ful discontinuation of IS therapy), 18 CR subjects
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8 healthy control (N) subjects. Using SAM, a 3-class
comparison identified 223 differentially expressed
genes. Importantly, these results support a state of re-
duced immune response in TOL subjects. Using this
signature, PAM correctly classified 16 of 18 CR sub-
jects, and 5 of 8 TOL subjects. A test set from this orig-
inal sample consisted of 4 TOL subjects and 3 CR
subjects, which were tested at a second time point
.12 months from the original sample. Using the 223
gene signature, PAM correctly classified TOL and
CR subjects with 98.2% and 92.9% accuracy, respec-
tively. The high degree of accuracy of this classifier
in a test sample supports the validity of these findings.
Martinez-Llordella et al. [67] first studied gene
expression and cell surface immunophenotyping in
PBMC of hepatic allograft recipients. Microarray
experiments utilized the Affymetrix U133 plus 2.0
array. TheTOL group was defined as those with stable
graft function .1 year out from successful IS discon-
tinuation. Importantly, the definition of the nontoler-
ant comparator here differs from Brouard and Braud;
this was here defined as those termed ‘‘immunosup-
pressive dependent’’ (ID). In these subjects, weaning
was attempted, but led to acute rejection, requiring
reintroduction of IS; the sample in these cases was
taken at least 2 years after the complete resolution of
the rejection episode. The training set in this experi-
ment consisted of 16 TOL subjects, 16 ID subjects,
and 10 healthy controls. Using the method BADGE
analysis, the investigators identified 462 upregulated
and 166 downregulated genes in TOL compared to
ID subjects. Validation was performed first by the
‘‘leave one out’’ crossvalidation technique, demon-
strating an accuracy of 94.12% in classifying TOL
and ID, as well as with RT-PCR.
Through this work, the investigators identified
a gene expression signature able to distinguish tolerant
from nontolerant hepatic allograft recipients, with
enrichment for genes for gdT and NK cells, and those
involved in cell proliferation arrest. As well, they
demonstrated by immunophenotyping enrichment
for regulatory and Vgd1 1 T cells in tolerant subjects
[60,67-75].
In subsequent work, Martinez-Llordella et al. [76]
examined gene expression profiling in a larger cohort
of hepatic allograft recipients with the aim of develop-
ing a signature for operational tolerance. Utilizing
RNA obtained from patient PBMC samples in an
Affymetrix oligonucleotide Human Genome U133
Plus 2.0 array, a total sample of 80 hepatic allograft re-
cipients and 16 healthy controls (N) were studied. The
TOL subjects were defined as those intentionally
weaned from immunosuppression having successfully
met the following criteria including: greater than
3 years posttransplantation, single-drug IS, absence
of acute rejection in previous 12 months, absence ofsigns of acute/CR in liver histology, absence of auto-
immune liver disease before or after transplantation,
and having samples collected at least 1 year after suc-
cessful discontinuation of IS. In nontolerant (non-
TOL) comparators, drug weaning was attempted,
but led to acute rejection requiring reintroduction of
IS drugs; samples were taken at more than 1 year after
complete resolution of the acute rejection episode.
Control subjects were healthy age-matched controls.
First, differential gene expression was studied in
a training set consisting of 17 TOL and 21 non-
TOL patients using SAM, whereby 1932 genes were
differentially expressed between TOL and non-
TOL. Then, PAM was used to identify the minimal
set of genes capable of predicting the tolerant state,
leading to the identification of a 24-gene signature
that correctly classified TOL versus non-TOL
patients with a sensitivity of 1 and specificity of
0.944. Importantly, NK, gdTCR1, and Vd1TCR1
peripheral blood lymphocyte proportions correlated
with the expression of multiple individual genes
included in the PAM-derived 24-gene set. This signa-
ture developed by PAM analysis was then applied to
a group (n5 19) of STA allograft recipients to estimate
the proportion who were potentially tolerant; toler-
ance was predicted in 26% of these cases.
As validation, qPCRwas performed in an indepen-
dent validation sample (16 TOL, 15 non-TOL, and
16 N), examining a panel of genes; these included the
24 genes identified by PAM analysis, as well as an
additional 44 genes selected from those most highly
ranked in the SAM-derived list, and also 6 other genes
relevant to tolerance from the literature. Using qPCR,
the investigators confirmed the differential expression
of 64% of the genes selected by microarray. Validation
was also performed using qPCR gene models in
a miPP algorithm in a separate cohort of 11 TOL
and 12 non-TOL subjects, resulting in an error rate
of 3% to 6% [76]. In summary, these data demonstrate
the following: The differential gene expression associ-
ated with hepatic allograft tolerance is largely com-
prised of genes coding for NK cell surface receptors;
a significant association exists between the expression
levels of the most informative genes and peripheral
blood (PB), NK, and gdTCR1 T cell frequencies; fi-
nally, the gdTCR1 T cell subset influences the ob-
served tolerance-related gene signature [76]. These
findings support the previous work from the investiga-
tors, and highlight potential differences in relative im-
mune cell composition and associated gene expression
compared to that reported in tolerant renal allograft
recipients.
Kawasaki et al. [77] have studied differential gene ex-
pression in11 tolerant (TOL)hepatic allograft recipients
compared tohealthy controls (N); no information is pro-
vided regarding the selection andnumberof healthy con-
trols.Additionally, this investigationdoesnot involveany
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were effectively tapered from tacrolimus in a planned
liberation scheme.The remaining5patients had ISwith-
drawn after either Ebstein-Barr virus (EBV) reactivation
or development of a posttransplant lymphoproliferative
disorder (PTLD). In the study of differential gene
expression from PBMC in tolerant hepatic allograft
recipients on an Agilent human cDNA microarray plat-
form, the investigators reported at total of 717geneswith
more than 2-fold difference in expression inTOL versus
N subjects; 627 were upregulated, and 90 were downre-
gulated in TOL subjects compared with controls. As
validation, RT-PCR is performed in this sample for
only 10 genes in total; the authors justify this approach
based on the premise that these genes were markedly
altered, and also assumed to be related to immune func-
tion and tolerance.
From this work, several interesting findings
emerge: First, in keeping with other reports, the toler-
ant group demonstrated decreased expression of genes,
including interleukin (IL_-1a, IL-1b, IL-8), SOCS3,
GR-a, and COX2, associated with immune response.
Second, several genes demonstrate increased expres-
sion: STAT1 is known to have a role in regulatory
T cell development and maintenance of tolerance
[78]; C3 is involved in transplantation tolerance
[79,80]; CBL, a ubiquitin protein ligase, is known to
be upregulated in T cells after tolerizing signals, and
its deficiency leads to an autoimmune syndrome in
murine systems [81,82]; finally, ID3 is associated
with inhibition of T cells, and promotion of NK cells
[77,83,84]. These results demonstrate the differential
gene expression manifest in the tolerant state com-
pared to healthy comparators. The specific genes
differentially expressed support both previous experi-
mental evidence, as well as coalesce with other findings
from the above reviewed studies to bring together
a model of transplantation tolerance associated gene
expression.CHALLENGES IN EXPERIMENTAL DESIGN
AND INTERPRETATION
A major challenge in the design and interpreta-
tion of this work is discerning changes in gene ex-
pression that truly dissect the tolerant state from
nontolerant compared to those resulting from the ab-
sence or presence of IS agents, and similarly the ab-
sence or presence of allograft rejection. These
investigators bolster their findings as truly reflecting
the tolerant state in the following ways: In Brouard,
Braud, and Martinez-Llordella, gene expression in
the tolerant group is compared to both a nontolerant
comparator (either chronic rejection in Brouard and
Braud, or nontolerant as defined as those who failed
a prior attempt at weaning of IS in Martinez-
Llordella et al.) as well as to healthy controls[55,66,76]. In this way, they assert that the changes
in gene expression that constitute the tolerant signa-
ture are distinct from both nontolerant individuals
and healthy controls, which have not been treated
with IS therapy. Second, Brouard et al. [55] note
that 4 of the 11 CR comparators were entirely off
IS, given that they had failed IS and had resumed he-
modialysis; on unsupervised analysis, those with CR
on IS and those with CR off IS clustered together,
suggesting that IS does not obscure the CR profile
in these patients. Next, both Brouard et al [55] and
Martinez-Llordella et al. [76] have examined the im-
pact of IS on the expression profiles observed; in both
cases, IS does not appear to be a significant con-
founder. Finally, Martinez-Llordella et al. [76] also
report that the STA (stable on IS) patients predicted
to be tolerant group together with TOL patients,
such that they share a common expression signature
despite the fact that the former is on IS, and the latter
is not. Allowing for the confines of their experimental
design, these arguments lend credence to the results,
truly reflecting a state of immune tolerance.
Other important potentially confounding variables
in these analyses have been addressed in the following
ways: Brouard et al. [55] used SASmultivariate analysis
and SAM quantitative analysis to examine variables
including allograft recipient age, sex, type of IS, prior
history of malignancy, cyyometalovirus (CMV) infec-
tion, and relative cellular composition of the PBMC
(with attention to PMN, lymphocytes, and mono-
cytes). Age-related differences were seen in 6 genes,
but their expression was more closely correlated with
the TOL class than with age, and remained signifi-
cantly different between the TOL, MIS, STA, and
CR groups. Otherwise, no other significant relation-
ships were detected between these variables and the
gene expression, including the cell composition of
the PBMC samples between patients. Similarly, Marti-
nez-Llordella et al. [76] utilized the Globaltest algo-
rithm to address the impact of these potential
confounders. This method is based on an empirical
Bayesian generalized linear model and is used to deter-
mine if an expression pattern of a group of genes is
related to a clinical variable. The variables examined
included the following: recipient age, sex, type of
IS, time from transplantation, PBMC composition
(lymphocyte, neutrophil, and monocytes), and hepati-
tis C (HCV) infection status. There was no significant
correlation between TOL-related expression profile
and age, sex, IS, or the PB counts. Time from trans-
plant was associated (P\ .042) with PAM.HCV status
had a significant impact on global gene expression and
on the TOL expression signature (P\ .0003).
Finally, there are significant differences in the
methodology of these studies that may limit compari-
sons: the type of allograft under consideration includes
renal and hepatic allografts, in which tolerance
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hematopoietic cells may participate in mediating cen-
tral tolerance in the thymic microenvironment in he-
patic allograft recipients [85-89]; however, the extent
to which donor microchimerism facilitates tolerance
by this mechanism in renal allograft recipients is
thought to be limited. Second, clinical definitions of
tolerance across studies differ, with variable patient
populations in regard to reasons for stopping IS as
well as requirements for duration of time required
off immunosuppression across studies. Next, the
‘‘nontolerant’’ comparator groups differ across studies,
including CR in Brouard and Braud, but rather non-
tolerant as defined by failure of previous attempt at
IS liberation in Martinez-Llordella et al. [76]. In
Kawasaki et al. [77], tolerant subjects are compared
to healthy controls alone. As well, importantly the mi-
croarray platforms (cDNA versus oligonucleotide) and
analysis methods utilized between these studies differ,
which limits the ability to synthesize these findings and
draw conclusions regarding tolerance associated gene
expression. For example, Martinez-Llordella et al.
[76] describe that the lymphochip and Affymetrix
U133 Plus 2.0 arrays share only 4,733 probes, and
that only 543 of them are present in the SAM-derived
2482-gene list discriminating between TOL and non-
TOL liver recipients in his study. The different
methods employed between studies may account in
part for their divergent findings. Comparisons across
studies and further progress in the field would be facil-
itated by more uniformity in the methods utilized.
Acknowledging these challenges, a comparative analy-
sis across these studies demonstrated the following:
first, examining the gene lists provided by each, there
is limited overlap, with only 12 genes shared across
at least 2 of these studies. Given the limited number
of overlapping genes, we examined the pathways
involved usingMetaCore software by GeneGo. A total
of 66 individual pathways were identified as differen-
tially expressed in tolerant versus nontolerant subjects
with a cutoff P-value of\.01. The top 20 are listed
in Table 1. The majority of these pathways group to
the cell processes of immune response, and cytokine
signaling.EMERGING MODEL OF TOLERANCE-
ASSOCIATED GENE EXPRESSION
Although there are potential challenges in the
direct comparison of these studies, in total, changes
in gene expression in tolerant individuals represented
here in large part recapitulate mechanisms of immune
tolerance supported by previous experimental evi-
dence. One nearly consistent finding across these
studies is that of reduced expression of genes impor-
tant for immune activation and response, overall de-
picting a state of immune quiescence. Of particularimportance, in Brouard et al. [55], are genes reflect-
ing reduced immune response, apoptosis, and growth
arrest that have been demonstrated to be under the
control of TGF-b. Supporting another major mecha-
nism of immune tolerance, Brouard et al. [55] dem-
onstrate decreased expression of genes related to
costimulatory signaling. Additionally, several of these
reports support the importance of regulatory T cells:
in the tolerant subjects, Brouard et al. [55] report in-
creased FOXP3 expression, Martinez-Llordella et al.
describe increased proportions of regulatory T cells
by immunophenotyping, and Kawasaki et al. [77]
report increased expression of STAT1, which has
established importance in regulatory T cell develop-
ment [55,68,77]. Not specifically supported by the
other studies, Martinez-Llordella et al. [67] demon-
strate increased numbers and enrichment for genes
expressed by gdT cells, enrichment for genes ex-
pressed by NK cells, and a polarization toward
Vgd11 subtype predominance among the gdT cell
population.TOLERANCE IN ALLOGENEIC HCT
Utilizing gene expression profiling, investigators
have begun to define the molecular underpinnings
of transplantation tolerance. Although this begins to
make possible an informed strategy for IS liberation,
the application to solid-organ transplantation re-
mains limited; a minority of solid organ allograft re-
cipients will successfully liberate from IS. This work
is far more relevant to HCT, wherein the majority of
transplant patients will eventually liberate from IS.
However, basic understanding of immune tolerance
development after HCT is limited, and the clinical
practice surrounding immunosuppressive liberation
after HCT is empiric. Through the use of successive
generations of IS regimens, GVHD has been more
effectively prevented, but this protection is incom-
plete [90-97]. Acute and later chronic GVHD
(aGVHD, cGVHD), as well as recurrent GVHD in
the setting of IS liberation after HCT clearly demon-
strate the inadequacy of the empiric approach cur-
rently employed [98-102]. Early efforts aimed at
defining risk of GVHD through microarray and pro-
teomic approaches have demonstrated the power and
relevance of an individualized approach [103,104].
The state of knowledge regarding IS requirements
and mechanisms of tolerance remains limited, how-
ever, and a rational strategy for IS liberation after
HCT is lacking [105]. The development of a toler-
ance-associated gene expression profile after HCT
would provide insight into the molecular mechanisms
of tolerance in HCT; the relative lack of agreement
in tolerance-associated gene expression between renal
and hepatic allograft investigation to date suggests
the importance of specifically examining this in
Table 1. Pathway Analysis of Differentially Expressed Genes Across Tolerant and Nontolerant Comparator Groups
Map Map Folders Cell Process P-Value
Genes (Involved)
(Total)
Immune response_Antigen
presentation by MHC class II
Regulatory processes/Immune response immune response 7.66E-08 8 73
Bacterial infections in CF airways Congenital, hereditary, and neonatal
disease and abnormalities-disease
maps/lung diseases/cystic fibrosis
1.36E-05 8 144
Immune response_NF-AT signaling
and leukocyte interactions
Protein function/cyto/chemokines
regulatory processes/immune response
immune response, cytokine-
mediated signaling pathway
1.87E-05 11 301
Immune response_IL-22
signaling pathway
Protein function/cyto/chemokines
regulatory processes/Immune response
immune response, cytokine-
mediated signaling pathway
3.61E-05 8 165
Immune response_role of
integrins in NK cells cytotoxicity
Regulatory processes/immune response immune response 5.19E-05 7 128
Immune response_Th1 and
Th2 cell differentiation
Protein function/cyto/chemokines
regulatory processes/development/
immune system development regulatory
processes/immune response
immune response, cytokine-mediated
signaling pathway, response to
extracellular stimulus
7.21E-05 8 182
Immune response_TLR signaling
pathways
Regulatory processes/immune response/
acute inflammatory response
immune response 8.74E-05 7 139
Immune response_BCR pathway Regulatory processes/immune response immune response 1.43E-04 8 201
Immune response_IL-1
signaling pathway
Protein function/cyto/chemokines
regulatory processes/Immune response/
acute inflammatory response
cytokine-mediated signaling
pathway, immune response
2.01E-04 7 159
Immune response_T cell receptor
signaling pathway
Regulatory processes/immune response immune response 2.65E-04 8 220
Cell adhesion_role of tetraspanins in
the integrin-mediated cell adhesion
Regulatory processes/cell adhesion cell adhesion 2.72E-04 7 167
Immune response_TREM1
signaling pathway
Regulatory processes/immune
response/acute inflammatory response
immune response 3.25E-04 7 172
Development_EGFR
signaling via PIP3
Protein function/growth factors
protein function/second messenger
regulatory processes/development/
epidermal cell development
intracellular receptor-mediated
signaling pathway, second-
messenger-mediated signaling,
response to extracellular stimulus
3.36E-04 5 80
Immune response_MIF in
innate immunity response
Regulatory processes/immune response/
acute inflammatory response
immune response 3.47E-04 6 124
Glycolysis and gluconeogenesis
p. 2/human version
Metabolic maps/organism-specific
metabolic maps for mouse, rat, and
human/carbohydrates metabolism
4.16E-04 4 47
Immune response_PGE2
signaling in immune response
Regulatory processes/development/
immune system development
Regulatory processes/Immune
response
immune response, response to
extracellular stimulus
4.46E-04 6 130
Chemotaxis_leukocyte chemotaxis Protein function/cyto/chemokines
regulatory processes/cell adhesion
regulatory processes/chemotaxis
regulatory processes/immune response
cell adhesion, immune response,
cytokine-mediated signaling
pathway
4.80E-04 9 302
Immune response_bacterial
infections in normal airways
Congenital, hereditary, and neonatal
diseases and abnormalities-disease
maps/lung diseases/cystic fibrosis
regulatory processes/immune response
immune response 5.03E-04 6 133
Immune response_IL-9
signaling pathway
Protein function/cyto/chemokines
regulatory processes/development/
immune system development regulatory
processes/immune response
immune response, cytokine-mediated
signaling pathway, response to
extracellular stimulus
5.24E-04 6 134
Cell adhesion_chemokines
and adhesion
Congenital, hereditary, and neonatal
diseases and abnormalities-protein
function/cyto/chemokines regulatory
processes/cell adhesion
cell adhesion, cytokine-mediated
signaling pathway
6.84E-04 11 455
MHC indicates major histocompatibility complex; NK, natural killer; EGFR, epidermal growth factor receptor; CF , cystic fibrosis.
*Comparison involves tolerant versus nontolerant clinical groups in Brouard, Braud, and Martinez-Llordella, and rather tolerant versus control subjects
in Kawasaki et al. [77].
*Pathway analysis performed using MetaCore by GeneGo.
*Genes involved: total number of differentially expressed genes from primary references involved in each pathway.
*Genes total: the total number of genes involved in each pathway.
Biol Blood Marrow Transplant 16:729-738, 2010 735Biomarkers to Discern Transplantation Tolerance after Allogeneic HCTHCT. As well, an informed strategy of IS liberation,
based on tolerance associated biomarkers, could im-
prove clinical practice by reducing the burden of
recurrent GVHD and its associated complications.The deficiencies in our knowledge of immune toler-
ance and management of IS after HCT make clear
the rationale for pursuing this investigation specifi-
cally in this setting.
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